These findings indicate that the combination of TRAIL andchemotherapeutic drugs is potentially promising in treating refractory cancers.TRAIL can induce human cancer cell apoptosis through the engagement of itsdeath receptors (DRs) DR4 and DR5. This evidence concerns the gene TNFRSF10B and cancer.